Han Yu Pharmaceuticals has acquired shares in Carbon Cloud Intelligence Peptides, deepening the synergy in AI peptide drug development and industrialization.

According to the news from Hanyu Pharmaceutical, recently, Hanyu Pharmaceutical has officially reached a strategic investment cooperation with Shenzhen Carbon Cloud Smart Peptide Drug Technology Co., Ltd. According to the agreement, Hanyu Pharmaceutical will subscribe for 10 million yuan in cash to increase the registered capital of Carbon Cloud Smart Peptide, holding 0.6623% equity after the capital increase. This signifies that the two parties have moved from the early stage research and development cooperation to a deep cooperation stage of capital binding and industrial synergy.